TABLE 4.
Summary of findings.
| Cohort recruitment criteria | Findings |
|---|---|
| More participants recruited while cognitively normal | Older participants (at intake and death) |
| Longer study follow‐up | |
| More females | |
| More CVD clinically | |
| More infarcts at autopsy | |
| More intermediate ADNC | |
| More participants recruited while cognitively impaired | Younger participants |
| More males | |
| More APOE ε4 (though not statistically significant at the p=0.05 level) | |
| More severe ADNC | |
| More clinical DLB at last UDS visit | |
| More clinical FTD at last UDS visit and FTLD‐TDP at autopsy | |
| (Percent with primary final clinical diagnosis of AD was not different according to cohort selection criteria) | |
Abbreviations: AD, Alzheimer's disease; ADNC, Alzheimer's disease neuropathologic change; APOE, apolipoprotein E; CVD; cardiovascular disease; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; FTLD‐TDP, frontotemporal lobar degeneration with TAR DNA‐binding protein 43, UDS, Uniform Data Set.